QUESTIONS TO ASK BEFORE ENROLLING
IN A CANCER CLINICAL TRIAL

Clinical trials are how new cancer therapies are tested, refined, and brought to standard care. Many of today's life-extending and life-saving treatments — modern immunotherapy, CAR-T cell therapy, targeted agents — exist because patients before agreed to participate in trials. For many patients with relapsed or refractory disease, a well-chosen trial is one of the strongest options available, sometimes the only option. But not every trial fits every patient. Trials are designed to answer specific scientific questions, and they are structured around inclusion and exclusion criteria, defined treatment schedules, and required tests. The therapy under study is by definition not yet proven, which means more uncertainty than with approved treatments. For some patients the trial is a meaningful step forward; for others, the trial is not the right fit and a different approach would serve them better. Asking the right questions before consent does three things at once. It helps the patient understand what is actually being offered, which is the foundation of informed consent. It often surfaces practical issues — schedule, cost, side effects, follow-up — that are easier to address before enrolment than after. And it builds a clearer dialogue between the patient, the trial team, and the local oncologist, which makes the rest of the journey smoother.

The phase of a trial says a lot about its purpose, what is known so far, and how it is structured. Phase 1 Phase 1 trials are usually the first time a new drug, device, or cell therapy is tested in humans for a particular indication. The main goal is safety — finding the right dose, identifying side effects, and confirming basic feasibility. Phase 1 trials are smaller, often involve dose escalation, and accept patients with limited remaining options. The chance of dramatic personal benefit is uncertain, although meaningful responses do occur. For patients with relapsed or refractory disease who have exhausted standard care, a Phase 1 trial of a promising new therapy can be a reasonable next step. Phase 2 Phase 2 trials test whether the therapy actually works in a particular cancer or population, after Phase 1 has established a dose. They are larger than Phase 1 and produce stronger signals of activity, while continuing to track safety. Many cell therapy and biomarker-guided trials in China sit at the Phase 2 level, with response rates and durability data that increasingly inform real-world practice. Phase 3 Phase 3 trials compare the experimental therapy with the current standard of care, usually in a randomised design. They are larger, longer, and produce the data that regulatory authorities like the FDA, EMA, and NMPA use to approve new treatments. For patients in early or earlier-line settings, a Phase 3 trial can offer access to a potentially better option than current standard, with the trade-off of being randomised — meaning the patient may receive the experimental therapy or the current standard, often unknowingly. Phase 4 Phase 4 trials are conducted after a therapy is already approved, to study long-term safety, real-world outcomes, and additional indications. They are usually less intensive operationally than earlier-phase trials.

1. What Is the Goal of This Trial? Every trial is designed to answer a specific question. Knowing the question helps the patient understand what success and failure look like in the trial's terms, which is not always the same as personal benefit. Suggested questions: What is the primary endpoint of the trial? Is it response rate, progression-free survival, overall survival, safety, or biomarker change? What does the trial expect to learn even if it does not work as hoped? 2. What Phase Is the Trial? Phase determines what is already known about the therapy and what is still being studied. Suggested questions: Is this Phase 1, 2, or 3? How many patients have already received this therapy in this trial or earlier studies? What kinds of responses or side effects have been reported so far? Where can I read or be told about preliminary data? 3. What Are the Inclusion and Exclusion Criteria? Trials accept only specific patient profiles. Knowing the exact criteria helps the patient understand whether they qualify and whether any aspect of their case might fail screening. Suggested questions: What are the specific inclusion criteria for my diagnosis, stage, prior therapy, and biomarkers? What are the exclusion criteria? Is there flexibility on any of these, or are they strict? If I do not currently meet a criterion (for example, a slightly low blood count), can it be addressed during screening? 4. What Tests Are Required Before Enrolment? Screening tests vary widely. Some trials need a fresh biopsy or pathology re-review; others need extensive imaging or specific molecular testing. Suggested questions: What screening tests are required, and how long do they take? Will I need a new biopsy, or will existing tissue be acceptable? Are there imaging studies, cardiac assessments, or specialised lab work I should arrange in advance? Who pays for screening tests, and what happens to my eligibility if a screening test fails? 5. What Does the Treatment Schedule Actually Look Like? The day-to-day reality of trial participation matters as much as the science. Suggested questions: How often do I need to be at the trial site, and for how long each visit? Will I be admitted as an inpatient, treated as an outpatient, or both? What is the planned duration of treatment? How long does the follow-up phase continue after treatment? Are there any procedures (lumbar puncture, repeat biopsy, prolonged blood sampling) that I should expect? 6. What Are the Possible Side Effects? All trials disclose known and expected side effects in the consent document. The trial team should explain these in plain language, including the most common, the most serious, and the rare but important ones. Suggested questions: What are the most common side effects expected, and how are they managed? Are there serious or life-threatening risks I should be aware of? How will side effects be monitored? What happens if I develop a serious side effect — does treatment pause, change, or stop? For cell therapy: what is the CRS and ICANS risk profile and management plan? 7. What Costs Are Covered and What Are Not? Cost structures in trials vary widely. Some trials provide the investigational product at no cost; others charge commercial pricing. Hospital admission, supportive care, screening tests, accommodation, and follow-up may or may not be included. Suggested questions: Is the experimental therapy itself provided at no cost, partially subsidised, or charged at commercial pricing? Which screening and on-trial tests are covered? Who pays for hospital admission, supportive medications, and ICU care if needed? Are accommodation, travel, and interpreter support included for international patients? What does follow-up after the trial cost? 8. What Happens If the Treatment Does Not Work? This is one of the most important and most often underemphasised questions. Trials sometimes fail at the individual patient level even when the science is sound at the trial level. Suggested questions: How will progression be defined and monitored during the trial? If the experimental therapy does not work for me, what are the next-line options? Will the trial team help coordinate the next step, or will I need to return to my home oncologist? Are there bridging therapies the trial allows during screening or while waiting for the next step? Is enrolment in this trial likely to affect my eligibility for other future trials? 9. What Is My Right to Withdraw? Trial participation is voluntary, and patients have the right to withdraw. The conditions of withdrawal and what happens to the patient afterwards are part of every consent document. Suggested questions: Can I withdraw from the trial at any time, and how is that done? If I withdraw, will my care continue at this hospital or transfer back to my local team? Will there be follow-up data collection after I withdraw, and what is collected? 10. How Will My Data and Privacy Be Handled? Trial data are collected, analysed, and often shared with regulatory authorities, sponsors, and academic publications, usually in de-identified form. Suggested questions: What information about me will be collected? With whom is it shared, and in what form? How long is it stored? Will my biological samples (blood, tissue) be used in the trial only or also for future research? 11. Who Is Sponsoring This Trial? Knowing who runs the trial — an academic group, a pharmaceutical company, a biotechnology firm, or a hospital consortium — helps patients understand the regulatory and operational context. Suggested questions: Who is the sponsor of this trial? Is the sponsor a hospital, academic group, biotech, or pharmaceutical company? Are the trial procedures reviewed by an independent ethics committee or institutional review board? 12. How Does This Trial Fit My Whole Treatment Plan? A trial is rarely the entire treatment plan; it is one step. Suggested questions: How does this trial fit with my prior therapy and likely future therapy? If the trial works, what consolidation or maintenance is planned? If I respond and then relapse later, what comes next? Has my local oncologist seen the proposal and does it match the broader strategy?

This comparison is general. Trials and approved therapy are often used in sequence rather than as alternatives. The right choice depends on the specific cancer, prior therapy, and what each pathway realistically offers.

Modern cancer clinical trials are conducted under multiple layers of safety and ethical oversight. Patients should expect: Patients should be cautious of any "trial" that does not provide a written consent document, that does not name an ethics committee, that promises guaranteed results, that asks for unusual upfront fees, or that does not allow withdrawal. These are warning signs of an unregulated programme rather than a legitimate clinical trial. CancerFax does not coordinate participation in unregulated treatment programmes.

• Approval by an institutional review board or ethics committe

  Approval by an institutional review board or ethics committee independent of the trial sponsor

• Compliance with international good clinical practice (GCP) s

  Compliance with international good clinical practice (GCP) standards

• A formal informed consent process, with the right to ask que

  A formal informed consent process, with the right to ask questions, take time, and decline without affecting standard care

• Data and safety monitoring during the trial, with the abilit

  Data and safety monitoring during the trial, with the ability to stop or modify the protocol if unexpected safety issues arise

• Adverse event reporting to regulatory authorities

  Adverse event reporting to regulatory authorities

• The right to withdraw at any time without losing access to s

  The right to withdraw at any time without losing access to standard care at that hospital or at home

Frequently Asked Questions

Answers to common questions from patients and families.

This guide is for patient education and care navigation support only. It does not replace the formal informed consent process for any specific clinical trial, which is conducted by the trial investigators and required for legal and ethical participation. CancerFax does not sponsor or run clinical trials. The role of CancerFax is to help patients evaluate trial suitability, prepare for informed consent conversations, and connect with trial teams for screening. Enrolment is never guaranteed. Eligibility, treatment choice, response, side effects, cost, and outcomes vary from patient to patient. This page does not replace medical advice from a qualified oncologist. CancerFax does not provide emergency medical care. Patients with breathing difficulty, severe bleeding, seizures, sudden weakness, uncontrolled pain, fever during treatment, or rapidly worsening symptoms should contact their treating hospital or emergency services immediately.

Structured reference data summarizing key information for this topic.